| Name | acebilustat |
|---|---|
| Synonyms |
Benzoic acid, 4-[[(1S,4S)-5-[[4-[4-(2-oxazolyl)phenoxy]phenyl]methyl]-2,5-diazabicyclo[2.2.1]hept-2-yl]methyl]-
4-{[(1S,4S)-5-{4-[4-(1,3-Oxazol-2-yl)phenoxy]benzyl}-2,5-diazabicyclo[2.2.1]hept-2-yl]methyl}benzoic acid acebilustat |
| Description | Acebilustat is a leukotriene A4 hydrolase inhibitor, used for an oral antiinflammatory drug. |
|---|---|
| Related Catalog | |
| In Vitro | Acebilustat is a leukotriene A4 hydrolase inhibitor, which is safe and well tolerated in phase 1 trial[1]. Acebilustat is an antiinflammatory drug in development for the treatment of CF and other diseases. It is a potent inhibitor of the enzyme leukotriene A4 hydrolase (LTA4H), which catalyzes the rate-limiting step in the formation of leukotriene B4 (LTB4), a potent chemoattractant and activator of inflammatory immune cells including neutrophils[2]. |
| References |
| Density | 1.3±0.1 g/cm3 |
|---|---|
| Boiling Point | 649.1±65.0 °C at 760 mmHg |
| Molecular Formula | C29H27N3O4 |
| Molecular Weight | 481.542 |
| Flash Point | 346.3±34.3 °C |
| Exact Mass | 481.200165 |
| LogP | 4.37 |
| Vapour Pressure | 0.0±2.0 mmHg at 25°C |
| Index of Refraction | 1.654 |
| Storage condition | 2-8℃ |